EXPERT NOTES:
CONTEXT: Peer Reviewed Data, RWE of Effectiveness of Cabozantinib
IMPACT: In the largest real-world study to date, cabozantinib was effective in unselected, heavily pretreated patients with mRCC. Initiation at 60 mg/day was associated with improved outcomes.
Time Taken = 4 mins
QUOTES FROM SOURCE:
1. “Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program Albiges L, Fléchon A, Chevreau C, et al European Journal of Cancer”
2. “December 16, 2020 Researchers undertook this multicentre (n = 26), observational, retrospective study (CABOREAL) to analyze treatment patterns as well as outcomes for patients with metastatic renal cell carcinoma (mRCC) managed with cabozantinib through the French Early Access Program.”
3. “Participants were patients with mRCC who had consumed ≥ 1 dose of cabozantinib.”
4. “Body mass index ≥ 25 kg/m2, prior nephrectomy, favourable or intermediate International Metastatic Renal Cell Carcinoma Database Consortium risk and cabozantinib initiation at 60 mg/day were identified as predictive factors related to longer OS.”
5. “Findings of this largest real-world study to date revealed the effectiveness of cabozantinib in unselected, heavily pretreated patients suffering from mRCC.”